---
schema_version: "secwatch.filing_event.v1"
accession: "0001809519-25-000035"
form_type: "8-K"
ticker: "GDRX"
cik: "0001809519"
company_name: "GoodRx Holdings, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:24:10.321894+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GoodRx reports Q4 revenue $198.6M, net income $6.7M; full-year revenue $792.3M, Adj. EBITDA $260.2M

## Summary
- Q4 2024 revenue of $198.6M, net income $6.7M (3.4% margin), Adjusted EBITDA $67.1M (33.8% margin).
- Full year 2024 revenue $792.3M, net income $16.4M (2.1% margin), Adjusted EBITDA $260.2M (32.8% margin).
- Q4 operating cash flow $44.7M, full-year $183.9M; over 7 million prescription consumers at quarter end.
- Results described as substantially in-line with previous guidance.

## SEC filing metadata
- accession: 0001809519-25-000035
- form_type: 8-K
- ticker: GDRX
- cik: 0001809519
- company_name: GoodRx Holdings, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1809519/000180951925000035/0001809519-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1809519/000180951925000035/gdrx-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001809519-25-000035
- JSON: https://secwatch.observer/filing/0001809519-25-000035.json
- Plain text: https://secwatch.observer/filing/0001809519-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.